Sugi Predict

Sugi Predict / Compounds / SCHEMBL3406540

SCHEMBL3406540

SCHEMBL3406540

COC(=O)c1[nH]nc2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.53
▸ STAT3 P40763 1/20 0.53
▸ HIF1A Q16665 1/20 0.53
▸ ALDH1A1 P00352 3/20 0.47
▸ GAA P10253 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ PADI4 Q9UM07 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ KDM4C Q9H3R0 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ NOS1 P29475 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ TNKS O95271 1/20 0.43
▸ NR4A2 P43354 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2723761 0.79 YTHDC1 (0.53) KDM4ESTAT3HIF1AALDH1A1SMN1; SMN2
SCHEMBL16516965 0.79 ALDH1A1 (0.44) KDM4ESTAT3HIF1AALDH1A1GAA
SCHEMBL16517475 0.79 ALDH1A1 (0.44) KDM4ESTAT3HIF1AALDH1A1GAA
SCHEMBL3405867 0.78 CYP1A2 (0.48) KDM4EALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL25399000 0.78 L3MBTL1 (0.45) KDM4ESTAT3HIF1AALDH1A1GAA
SCHEMBL27242667 0.78 MAP2K4 (0.48) KDM4EALDH1A1GAAHTTSMN1; SMN2
SCHEMBL20544877 0.78 HTR2A (0.50) KDM4EALDH1A1GAAHTTNPSR1
SCHEMBL20544550 0.78 KDM4E (0.52) KDM4EALDH1A1GAANPSR1SMN1; SMN2
SCHEMBL26875246 0.78 KDM4C (0.41) KDM4ESTAT3HIF1AALDH1A1GAA
SCHEMBL6649449 0.77 CYP1A2 (0.47) KDM4EALDH1A1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119462695-A Pyridine derivative and application thereof 康百达（四川）生物医药科技有限公司 2025-02-18 — — CN disclosed
EP-4385980-A1 INDAZOLES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2024-06-19 — — EP disclosed
CN-117120419-A KLK5 bicyclic heteroaromatic inhibitors 拜奥克里斯特制药公司 2023-11-24 — — CN disclosed
CN-110831942-B Fused indazolopyridinone compounds as antiviral agents 诺华股份有限公司 2023-04-04 — — CN disclosed
EP-3998269-A1 FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS Novartis AG (CH) 2022-05-18 — — EP disclosed
EP-3954681-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK Bristol-Myers Squibb Company (US) 2022-02-16 — — EP disclosed
EP-3402790-B1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2021-10-06 — — EP disclosed
EP-3615533-B1 FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS NOVARTIS AG (CH) 2021-09-08 — — EP disclosed
CN-108699038-B Spirocyclic heptane salicylamides and related compounds as Rock inhibitors 百时美施贵宝公司 2021-04-16 — — CN disclosed
US-10975078-B2 Fused indazole pyridone compounds as antivirals NOVARTIS AG (CH) 2021-04-13 — — US disclosed
CN-110831942-A Fused indazolopyridinone compounds as antiviral agents 诺华股份有限公司 2020-02-21 — — CN disclosed
US-20190300530-A1 FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS NOVARTIS AG (CH) 2019-10-03 — — US disclosed
US-20190300530-A1 FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS NOVARTIS AG (CH) 2019-10-03 — — US disclosed
US-10301312-B2 Fused indazole pyridone compounds as antivirals NOVARTIS AG (CH) 2019-05-28 — — US disclosed
US-10301312-B2 Fused indazole pyridone compounds as antivirals NOVARTIS AG (CH) 2019-05-28 — — US disclosed
US-20180312507-A1 FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS NOVARTIS AG (CH) 2018-11-01 — — US disclosed
WO-2018198079-A1 FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS NOVARTIS AG (CH) 2018-11-01 — — WO disclosed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 — — EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 — — US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 KDM4E 1965/4885STAT3 4645/4885HIF1A 311/4885
US-20190300530-A1 FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS CYP3A5, CYP3A43, CYP3A4 KDM4E 2113/4885STAT3 1448/4885HIF1A 3622/4885
US-20180312507-A1 FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS CYP3A5, CYP3A43, CYP3A4 KDM4E 2113/4885STAT3 1448/4885HIF1A 3622/4885
US-10301312-B2 Fused indazole pyridone compounds as antivirals CYP3A5, CYP3A43, CYP3A4 KDM4E 2113/4885STAT3 1448/4885HIF1A 3622/4885
US-10975078-B2 Fused indazole pyridone compounds as antivirals CYP3A5, CYP3A43, CYP3A4 KDM4E 2113/4885STAT3 1448/4885HIF1A 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.